CRISPR based editing of SIV proviral DNA in ART treated non-human primates.
Pietro MancusoChen ChenRafal KaminskiJennifer GordonShuren LiaoJake A RobinsonMandy D SmithHong LiuIlker K SariyerRahsan SariyerTiffany A PetersonMartina DonadoniJaclyn B WilliamsSummer SiddiquiBruce A BunnellBinhua LingAndrew G MacLeanTricia H BurdoKamel KhaliliPublished in: Nature communications (2020)
Elimination of HIV DNA from infected individuals remains a challenge in medicine. Here, we demonstrate that intravenous inoculation of SIV-infected macaques, a well-accepted non-human primate model of HIV infection, with adeno-associated virus 9 (AAV9)-CRISPR/Cas9 gene editing construct designed for eliminating proviral SIV DNA, leads to broad distribution of editing molecules and precise cleavage and removal of fragments of the integrated proviral DNA from the genome of infected blood cells and tissues known to be viral reservoirs including lymph nodes, spleen, bone marrow, and brain among others. Accordingly, AAV9-CRISPR treatment results in a reduction in the percent of proviral DNA in blood and tissues. These proof-of-concept observations offer a promising step toward the elimination of HIV reservoirs in the clinic.
Keyphrases
- crispr cas
- genome editing
- circulating tumor
- antiretroviral therapy
- cell free
- single molecule
- hiv infected
- bone marrow
- endothelial cells
- lymph node
- human immunodeficiency virus
- hepatitis c virus
- genome wide
- gene expression
- nucleic acid
- circulating tumor cells
- primary care
- mesenchymal stem cells
- sars cov
- high dose
- induced apoptosis
- brain injury
- white matter
- south africa
- induced pluripotent stem cells
- multiple sclerosis
- pluripotent stem cells
- dna binding
- newly diagnosed
- endoplasmic reticulum stress
- subarachnoid hemorrhage
- rectal cancer